Last reviewed · How we verify
NCT05182723
Evaluation of the Effectiveness of Extracorporeal Methods for Removing Mediators of Systemic Inflammation
NA trial testing renal replacement therapy in Renal Failure Acute in 20 participants. Status unknown.
30 November 2024
Quick facts
| Lead sponsor | Petrovsky National Research Centre of Surgery |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 25 November 2021 |
| Primary completion | 30 November 2024 |
| Estimated completion | 31 May 2025 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- renal replacement therapy
Conditions studied
- Renal Failure Acute — all drugs for Renal Failure Acute →
- Multiple Organ Failure — all drugs for Multiple Organ Failure →
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Sponsor
Petrovsky National Research Centre of Surgery — full company profile →
Who can join
18 and older, any sex, with Renal Failure Acute or Multiple Organ Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess the effectiveness and the safety of extracorporeal methods for removing mediators of systemic inflammation in patients with multiple organ dysfunction syndrome after heart and aorta surgery.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of Continuous Renal Replacement Therapy with the oXiris Hemofilter on Critically Ill Patients: A Narrative Review.
Li Y, Sun P, Chang K, Yang M, et al · · 2022 · cited 26× · PMID 36431196 · DOI 10.3390/jcm11226719
Verify or expand the search:
- PubMed search for NCT05182723
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of renal replacement therapy
Trials testing the same drug.
- NCT03912727 — Alpha Lipoic Acid Against Cardiovascular Events in Patients With Haemodialysis · NA · completed
Other Petrovsky National Research Centre of Surgery trials
Trials by the same sponsor.
- NCT07422246 — Prognosis and Diagnosis of Acute Gastrointestinal Dysfunction in Cardiac Surgery Patients · NA · not yet recruiting
- NCT06977646 — Surgical Treatment of the Patients With Restrictive Phenotype of the Hypertrophic Cardiomyopathy Without LVOT Obstructio · enrolling by invitation
- NCT07358416 — Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery. · active not recruiting
- NCT06336213 — Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients · NA · recruiting
- NCT06476171 — Validation of Hematological Indices · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05182723 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Petrovsky National Research Centre of Surgery
- Last refreshed: 3 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05182723.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing